MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1930

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1930-1934.doi: 10.16352/j.issn.1001-6325.2022.12.1930

MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

王玉敏¹, 陈济超^1*, 王洪权², 王金华³, 唐博²

1.航天中心医院北京大学航天临床医学院呼吸与危重症医学科,北京 100049;
2.天津医科大学肿瘤医院天津医科大学肿瘤研究所国家癌症临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心胰腺肿瘤科,天津 300060;
3.中国医学科学院北京协和医学院药物研究所天然药物活性物质与功能国家重点实验室药物靶点研究与新药筛选北京市重点实验室,北京 100050

收稿日期:2021-05-11 修回日期:2021-12-31 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* chen_htzxyy@sina.com
基金资助:
国家自然科学基金(81871938);北京市海淀区卫生健康发展科研培育计划(HP2021-19-50701);航天中心医院院级课题(YN202104);中国航天科工集团课题(2020-LCYL-009);航天医科科研课题(2020YK02)

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

WANG Yu-min¹, CHEN Ji-chao^1*, WANG Hong-quan², WANG Jin-hua³, TANG Bo²

1. Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049;
2. Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060;
3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, CAMS & PUMC, Beijing Key Laboratory of Drug Target and Screening Research, Beijing 100050,China

Received:2021-05-11 Revised:2021-12-31 Online:2022-12-05 Published:2022-11-23
Contact: ^* chen_htzxyy@sina.com

摘要/Abstract

摘要： 代谢重编程被认为是肿瘤细胞最重要的特征之一。微小RNAs(microRNAs)是一组多功能的非编码RNA,通过脂质代谢重编程在肝细胞癌(HCC)的发生发展中发挥重要作用。本文综述了microRNAs调控肝癌脂质代谢重编程的研究进展。

关键词: 肝细胞癌, 微小RNAs, 脂代谢重编程, 肿瘤发生

Abstract: Metabolic reprogramming is considered to be one of the top characteristics of tumor cells. Ample experimental studies have shown that microRNAs, which are a group of multifunctional non-coding RNAs, play an important role in the development of hepatocellular carcinoma (HCC) through lipid metabolic reprogramming. The current review briefly introduces the recent progress of specific microRNAs targeting at lipid metabolic reprogramming in HCC, which may provide a potential strategy for clinical targeting tumor therapy.

Key words: hepatocellular carcinoma, microRNAs, lipid metabolic reprogramming, tumorigenesis

中图分类号:

R735.7

王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.

WANG Yu-min, CHEN Ji-chao, WANG Hong-quan, WANG Jin-hua, TANG Bo. Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2022, 42(12): 1930-1934.

参考文献 14

[1]	Nakagawa H, Hayata Y, Kawamura S, et al. Lipid metabolic reprogramming in hepatocellular carcinoma[J]. Cancers (Basel), 2018,10:447.doi: 10.3390/cancers10110447.
[2]	Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight[J]. Nat Rev Cancer, 2013,13:227-232.
[3]	Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes[J]. Gastroenterology, 2013,144:1066-1075.
[4]	Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016,5:e189.doi: 10.1038/oncsis.2015.49.
[5]	Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, et al. The mitochondrial citrate carrier SLC25A1/CIC and the fundamental role of citrate in cancer, Inflammation and Beyond[J]. Biomolecules, 2021,11:141.doi: 10.3390/biom11020141.
[6]	Zhao G, Dong L, Shi H, et al. MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway[J]. Oncol Rep, 2016,36:1709-1716.
[7]	Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway[J]. Gut, 2016,65:1850-1860.
[8]	Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1[J]. Int J Oncol, 2014,45:2143-2152.
[9]	Li H, Chen Z, Zhang Y, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis[J]. Cancer Lett, 2021,519:161-171.
[10]	Lin YX, Wu XB, Zheng CW, et al. Mechanistic investigation on the regulation of FABP1 by the IL-6/miR-603 signaling in the pathogenesis of hepatocellular carcinoma[J]. Biomed Res Int, 2021:8579658.doi: 10.1155/2021/8579658.
[11]	Bai PS, Xia N, Sun H, et al. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipo-genesis in HBV-related hepatocellular carcinoma[J]. J Cell Mol Med, 2017,21:3023-3043.
[12]	Zare M, Panahi G, Koushki M, et al. Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b[J]. Arch Physiol Biochem, 2022,128:333-340.
[13]	Yuan P, Mu J, Wang Z, et al. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation[J]. Cell Death Dis, 2021,12:361.doi:10.1038/s41419-021-03648-1.
[14]	Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming[J]. J Hematol Oncol, 2020,13:12.doi: 10.1186/s13045-019-0841-3.

[1]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[2]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[3]	林映雪, 崔海鹏, 王爱国, 姚银辉, 赵娟. 雷帕霉素减缓转基因小鼠肝细胞癌进展[J]. 基础医学与临床, 2023, 43(8): 1241-1246.
[4]	邹瑾, 何向蕾, 张欣, 陈日萍, 张宇, 胡帅悦, 应士波. 蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达[J]. 基础医学与临床, 2023, 43(6): 898-903.
[5]	冀梦蝶, 苑赞, 卞晓翠, 杨玉容, 郭鑫, 王琦, 陈阳. 人肝癌细胞系HepG2和Huh7中的基因组拷贝数变异分析[J]. 基础医学与临床, 2023, 43(6): 960-966.
[6]	高欣, 于永波, 王海存, 姜兴明, 王志东. 环状RNA核受体相互作用蛋白1对肿瘤发生发展的调控机制研究进展[J]. 基础医学与临床, 2023, 43(5): 827-832.
[7]	刘爱霞, 张浩, 孙杰, 杨丽华, 赵晓涛. GPS2对肝癌细胞系MHCC-97H增殖、迁移与侵袭的调控作用[J]. 基础医学与临床, 2023, 43(12): 1784-1791.
[8]	查娜, 郝丹丹, 李天柱. microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展[J]. 基础医学与临床, 2023, 43(12): 1871-1875.
[9]	黄驿胜, 叶启文, 王竞枫. miR-203a-3p抑制人肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(1): 87-94.
[10]	周岚, 张生贵, 胡祖梁, 王添贤, 岳鹏鹏, 于鸿浩. 基于CRISPR/Cas9系统高效编辑小鼠miR let-7a[J]. 基础医学与临床, 2022, 42(6): 857-863.
[11]	赵钰珊, 冀梦蝶, 董昱诚, 郭鑫, 宋博渊, 陈阳. 肝细胞癌中EZH2基因相关的表观遗传调控机制[J]. 基础医学与临床, 2022, 42(6): 864-870.
[12]	张悦怡, 李美姿, 杨莹韵, 杨爱明. 含TPR干扰素诱导蛋白在消化系统肿瘤中作用的研究进展[J]. 基础医学与临床, 2021, 41(11): 1662-1665.
[13]	吴娜, 王东, 白咸勇. 细胞自噬与肝细胞癌的研究进展[J]. 基础医学与临床, 2021, 41(10): 1514-1517.
[14]	倪安妮, 梁清洋, 姚鸿飞, 李根亮, 唐玉莲. 花生四烯酸代谢基因对小鼠肝细胞癌中环氧化酶P450途径的影响[J]. 基础医学与临床, 2020, 40(8): 1053-1058.
[15]	曹明月, 李高翔, 陈昱竹, 黄薇, 杨楠, 刘雁勇. 儿茶酚胺类应激激素促进小鼠肝癌细胞系H22中G₀期细胞周期再入[J]. 基础医学与临床, 2020, 40(7): 897-902.

MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展

Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 15

编辑推荐

Metrics

本文评价